Streetbeat News

Regulatory

SPY

Federal Reserve Chair Jerome Powell did not address monetary policy or the economic outlook in his brief opening remarks at a New York Fed conference.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 1:20 pm

VRTX

Vertex Pharmaceuticals announced that Health Canada has accepted its New Drug Submission for the triple combination treatment Vanzacaftor/Tezacaftor/Deutivacaftor for cystic fibrosis. This marks a significant step in expanding the availability of their treatment options.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 1:04 pm

DE

John Deere has issued a recall for its compact utility tractors due to a crash hazard. This recall could impact the company's reputation and financial performance in the short term.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 1:04 pm

BABA

JD

NIO

XPEV

Chinese stocks are experiencing a rise in share prices due to a report indicating that China plans to issue up to $284 billion in sovereign debt as a stimulus measure.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:57 pm

ENLV

Enlivex has received approval from the Danish Medicines Agency to commence Phase II trials of Allocetra for moderate to severe knee osteoarthritis, following a positive safety review.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:44 pm

LBPH

Longboard Pharmaceuticals has initiated a Phase 3 study for its drug Bexicaserin, targeting seizures in Dravet syndrome. The study has begun with initial sites activated and more to follow soon.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:37 pm

AEYE

AudioEye has achieved HIPAA compliance and SOC 2 Type II certification, enhancing its credibility and trustworthiness in handling sensitive data. This development is significant for the company's operations in sectors requiring high data security standards, such as healthcare and finance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:33 pm

MPU

Mega Matrix has received shareholder approval to redomicile to the Cayman Islands, with the merger set to complete on October 8, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:32 pm

OVID

Ovid Therapeutics presented pre-clinical study results showing that their drug OV329 does not accumulate in animal eyes, unlike vigabatrin. This suggests a differentiated safety and efficacy profile. A Phase 1 trial is on track for completion in late 2024.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:19 pm

INZY

Inozyme Pharma presented new data at ASBMR 2024, emphasizing the urgent need for therapies for cardiovascular and musculoskeletal complications in ENPP1 and ABCC6 deficiencies. They also launched the PROPEL Registry to enhance understanding of these rare diseases.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:17 pm